|
|
|
 |
 |
 |
 |
 |
|
 |
|
|
|
 |
 |
 |
 |
 |
|
 |
|
|
|
On The Take: How Medicine's Complicity with Big Business Can Endanger Your Health |
|
|
|
 |
|
 |
 |
 |
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
|
|
|
| Publisher |
| Oxford University Press |
 |
| Published |
| September 2004 |
 |
| ISBN |
| 0195176847 |
 |
 |
 |
 |
| $28.00 |
|
List Price |
 |
| $18.48 |
|
OUR PRICE |
|
|
|
 |
 |
 |
| Sales Rank: |
|
11,180 |
|
|
 |
| AVAILABILITY: |
|
|
| Usually ships in 24 hours |
|
 |
|
|
|
|
 |
|
 |
 |
 |
 |
|
 |
|
|
|
 |
We all know that doctors accept gifts from drug companies, ranging from pens and coffee mugs to free vacations at luxurious resorts. But as the former Editor-in-Chief of The New England Journal of Medicine reveals in this shocking expose, these innocuous-seeming gifts are just the tip of an iceberg that is distorting the practice of medicine and jeopardizing the health of millions of Americans today. In On the Take, Dr. Jerome Kassirer offers an unsettling look at the pervasive payoffs that physicians take from big drug companies and other medical suppliers, arguing that the billion-dollar onslaught of industry money has deflected many physicians' moral compasses and directly impacted the everyday care we receive from the doctors and institutions we trust most. Underscored by countless chilling untold stories, the book illuminates the financial connections between the wealthy companies that make drugs and the doctors who prescribe them. Kassirer details the shocking extent of these financial enticements and explains how they encourage bias, promote dangerously misleading medical information, raise the cost of medical care, and breed distrust. Among the questionable practices he describes are: the disturbing number of senior academic physicians who have financial arrangements with drug companies; the unregulated "front" organizations that advocate certain drugs; the creation of biased medical education materials by the drug companies themselves; and the use of financially conflicted physicians to write clinical practice guidelines or to testify before the FDA in support of a particular drug. A brilliant diagnosis of an epidemic of greed, On the Take offers insight into how we can cure the medical profession and restore our trust in doctors and hospitals. |
 |
|
|
|
|
 |
|
 |
 |
 |
|
|
 |
Product Reviews |
 |
| Review this item. Coming soon! |
| Average rating: 5.0 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
| Big Pharma Out of Control |
|
Rating |
 |
| January 19, 2005 |
|
 |
 |
Fact-dense, well referenced, yet balanced in tone and easy to read, this book is the best exposé I have ever read on the financial conflicts of the medical profession caused by the efforts of Big Pharma, which for this review will include device and test manufacturers as well as drug makers. From pens and pads to cruises and fake consulting arrangements, Big Pharma has caused financial conflicts in many physicians and others "on the take". Many of the consulting deals are to give talks, ostensibly based on good medical science, that promote a product. Much of this is shown to occur at Continuing Medical Education courses sponsored by Big Pharma in which gifts are freely dispensed, reprints of journal articles favorable to products are handed out, and financial ties of the "consultants" giving talks are minimized or concealed.
Academic researchers are tainted as well. By being encouraged by their universities to obtain grants with overhead from Big Pharma, they must do research that helps in product development. Agreements may delay, prevent or pollute the publication of results. When a product possibility from a government (usually NIH) grant is seen, federal legislation passed 20 years ago allows the researcher to patent discoveries, form a company, and do clinical trials on his own potential product. While this may have led to valuable results, the potential for bias at every step due to financial conflict is clearly laid out.
Journals fare little better, even the prominent JAMA, NEJM and Annals of Internal Medicine. Papers that may have been ghost-written by Big Pharma on clinical trials with selectively favorable results are published [see Joel M. Kauffman, Bias in Recent Papers on Diets and Drugs in Peer-Reviewed Medical Journals, J. Am. Physicians & Surgeons, 9(1), 11-14 (2004)]. Editors and peer-reviewers may have ties to Big Pharma. Editorials and comments in medical journals may be written by authors with financial conflicts of interest. Revealing such conflicts is mostly on the honor system at present.
Clinical guidelines for physicians are promulgated by committees whose members often have close ties to Big Pharma. The products included in formularies of HMOs, Medicare and other insurers, the only products that will be paid for, are influenced by Big Pharma, whose general lobbying efforts are already legendary.
Dr. Kassirer gives many specific examples of financial conflicts. Far from quitting with the devastating description of how bad things are, he goes on to make specific suggestions for reform, while being very realistic about their success without federal action for certain conflicts. He lists many desirable changes, such as no gifts from Big Pharma at all, boycotting meetings sponsored by Big Pharma, disclosure mandated for all financial ties, and selection of journal editors, officers of medical societies and leaders of medical schools who have no financial conflicts. He did not seem to indicate the degree of influence of Big Pharma on the FDA.
Trying not to alienate most of the medical profession, Dr. Kassirer wrote that most MDs are basically ethical and went into the profession for non-financial as well as financial reasons. Reductions in income with increased work loads due to inadequate compensation from HMOs and Medicare is one of the reasons so many MDs have looked outside normal practice for income.
******
He dropped a few hints that most major classes of drugs are more beneficial than they actually are [see Joel M. Kauffman, "Drugging Cardiovascular Disease", J. Am. Physicians & Surgeons, 9(4), 98-99 (2004)], and that alternative practices are not worth much [see Joel M. Kauffman, "Alternative Medicine: Watching the Watchdogs at Quackwatch", Website Review, J. Scientific Exploration 16(2), 312-337 (2002)].
This is a very minor blemish on one of the great exposés of all time, the "Unsafe at Any Speed" of the medical madness in the USA today.
******
Daniel Haley's "Politics in Healing" describes the squashing of alternatives.
Charles T. McGee's "Heart Frauds" exposes the mythology behind so much medical advice.
H. Gilbert Welch's "Should I Be Tested for Cancer?" gives the evidence for the harm in excessive testing.
John Anderson's "Overdosed America" reveals the extent of perverted clinical drug trials.
Merrill Goozner's "The $800 Million Pill" give the lie to Big Pharma's claim that high prices are needed for the discovery of breakthrough drugs, as does...
Marcia Angell's "The Truth About the Drug Companies", which also suggests how the perversion of drug trials can be halted. |
 |
 |
 |
|
 |
 |
 |
| Big Pharma Out of Control |
|
Rating |
 |
| January 19, 2005 |
|
 |
 |
Fact-dense, well referenced, yet balanced in tone and easy to read, this book is the best exposé I have ever read on the financial conflicts of the medical profession caused by the efforts of Big Pharma, which for this review will include device and test manufacturers as well as drug makers. From pens and pads to cruises and fake consulting arrangements, Big Pharma has caused financial conflicts in many physicians and others "on the take". Many of the consulting deals are to give talks, ostensibly based on good medical science, that promote a product. Much of this is shown to occur at Continuing Medical Education courses sponsored by Big Pharma in which gifts are freely dispensed, reprints of journal articles favorable to products are handed out, and financial ties of the "consultants" giving talks are minimized or concealed.
Academic researchers are tainted as well. By being encouraged by their universities to obtain grants with overhead from Big Pharma, they must do research that helps in product development. Agreements may delay, prevent or pollute the publication of results. When a product possibility from a government (usually NIH) grant is seen, federal legislation passed 20 years ago allows the researcher to patent discoveries, form a company, and do clinical trials on his own potential product. While this may have led to valuable results, the potential for bias at every step due to financial conflict is clearly laid out.
Journals fare little better, even the prominent JAMA, NEJM and Annals of Internal Medicine. Papers that may have been ghost-written by Big Pharma on clinical trials with selectively favorable results are published [see Joel M. Kauffman, Bias in Recent Papers on Diets and Drugs in Peer-Reviewed Medical Journals, J. Am. Physicians & Surgeons, 9(1), 11-14 (2004)]. Editors and peer-reviewers may have ties to Big Pharma. Editorials and comments in medical journals may be written by authors with financial conflicts of interest. Revealing such conflicts is mostly on the honor system at present.
Clinical guidelines for physicians are promulgated by committees whose members often have close ties to Big Pharma. The products included in formularies of HMOs, Medicare and other insurers, the only products that will be paid for, are influenced by Big Pharma, whose general lobbying efforts are already legendary.
Dr. Kassirer gives many specific examples of financial conflicts. Far from quitting with the devastating description of how bad things are, he goes on to make specific suggestions for reform, while being very realistic about their success without federal action for certain conflicts. He lists many desirable changes, such as no gifts from Big Pharma at all, boycotting meetings sponsored by Big Pharma, disclosure mandated for all financial ties, and selection of journal editors, officers of medical societies and leaders of medical schools who have no financial conflicts. He did not seem to indicate the degree of influence of Big Pharma on the FDA.
Trying not to alienate most of the medical profession, Dr. Kassirer wrote that most MDs are basically ethical and went into the profession for non-financial as well as financial reasons. Reductions in income with increased work loads due to inadequate compensation from HMOs and Medicare is one of the reasons so many MDs have looked outside normal practice for income.
******
He dropped a few hints that most major classes of drugs are more beneficial than they actually are [see Joel M. Kauffman, "Drugging Cardiovascular Disease", J. Am. Physicians & Surgeons, 9(4), 98-99 (2004)], and that alternative practices are not worth much [see Joel M. Kauffman, "Alternative Medicine: Watching the Watchdogs at Quackwatch", Website Review, J. Scientific Exploration 16(2), 312-337 (2002)].
This is a very minor blemish on one of the great exposés of all time, the "Unsafe at Any Speed" of the medical madness in the USA today.
******
Daniel Haley's "Politics in Healing" describes the squashing of alternatives.
Charles T. McGee's "Heart Frauds" exposes the mythology behind so much medical advice.
H. Gilbert Welch's "Should I Be Tested for Cancer?" gives the evidence for the harm in excessive testing.
John Anderson's "Overdosed America" reveals the extent of perverted clinical drug trials.
Merrill Goozner's "The $800 Million Pill" give the lie to Big Pharma's claim that high prices are needed for the discovery of breakthrough drugs, as does...
Marcia Angell's "The Truth About the Drug Companies", which also suggests how the perversion of drug trials can be halted. |
 |
 |
 |
|
 |
 |
 |
| Big Pharma Out of Control |
|
Rating |
 |
| January 19, 2005 |
|
 |
 |
Fact-dense, well referenced, yet balanced in tone and easy to read, this book is the best exposé I have ever read on the financial conflicts of the medical profession caused by the efforts of Big Pharma, which for this review will include device and test manufacturers as well as drug makers. From pens and pads to cruises and fake consulting arrangements, Big Pharma has caused financial conflicts in many physicians and others "on the take". Many of the consulting deals are to give talks, ostensibly based on good medical science, that promote a product. Much of this is shown to occur at Continuing Medical Education courses sponsored by Big Pharma in which gifts are freely dispensed, reprints of journal articles favorable to products are handed out, and financial ties of the "consultants" giving talks are minimized or concealed.
Academic researchers are tainted as well. By being encouraged by their universities to obtain grants with overhead from Big Pharma, they must do research that helps in product development. Agreements may delay, prevent or pollute the publication of results. When a product possibility from a government (usually NIH) grant is seen, federal legislation passed 20 years ago allows the researcher to patent discoveries, form a company, and do clinical trials on his own potential product. While this may have led to valuable results, the potential for bias at every step due to financial conflict is clearly laid out.
Journals fare little better, even the prominent JAMA, NEJM and Annals of Internal Medicine. Papers that may have been ghost-written by Big Pharma on clinical trials with selectively favorable results are published [see Joel M. Kauffman, Bias in Recent Papers on Diets and Drugs in Peer-Reviewed Medical Journals, J. Am. Physicians & Surgeons, 9(1), 11-14 (2004)]. Editors and peer-reviewers may have ties to Big Pharma. Editorials and comments in medical journals may be written by authors with financial conflicts of interest. Revealing such conflicts is mostly on the honor system at present.
Clinical guidelines for physicians are promulgated by committees whose members often have close ties to Big Pharma. The products included in formularies of HMOs, Medicare and other insurers, the only products that will be paid for, are influenced by Big Pharma, whose general lobbying efforts are already legendary.
Dr. Kassirer gives many specific examples of financial conflicts. Far from quitting with the devastating description of how bad things are, he goes on to make specific suggestions for reform, while being very realistic about their success without federal action for certain conflicts. He lists many desirable changes, such as no gifts from Big Pharma at all, boycotting meetings sponsored by Big Pharma, disclosure mandated for all financial ties, and selection of journal editors, officers of medical societies and leaders of medical schools who have no financial conflicts. He did not seem to indicate the degree of influence of Big Pharma on the FDA.
Trying not to alienate most of the medical profession, Dr. Kassirer wrote that most MDs are basically ethical and went into the profession for non-financial as well as financial reasons. Reductions in income with increased work loads due to inadequate compensation from HMOs and Medicare is one of the reasons so many MDs have looked outside normal practice for income.
******
He dropped a few hints that most major classes of drugs are more beneficial than they actually are [see Joel M. Kauffman, "Drugging Cardiovascular Disease", J. Am. Physicians & Surgeons, 9(4), 98-99 (2004)], and that alternative practices are not worth much [see Joel M. Kauffman, "Alternative Medicine: Watching the Watchdogs at Quackwatch", Website Review, J. Scientific Exploration 16(2), 312-337 (2002)].
This is a very minor blemish on one of the great exposés of all time, the "Unsafe at Any Speed" of the medical madness in the USA today.
******
Daniel Haley's "Politics in Healing" describes the squashing of alternatives.
Charles T. McGee's "Heart Frauds" exposes the mythology behind so much medical advice.
H. Gilbert Welch's "Should I Be Tested for Cancer?" gives the evidence for the harm in excessive testing.
John Anderson's "Overdosed America" reveals the extent of perverted clinical drug trials.
Merrill Goozner's "The $800 Million Pill" give the lie to Big Pharma's claim that high prices are needed for the discovery of breakthrough drugs, as does...
Marcia Angell's "The Truth About the Drug Companies", which also suggests how the perversion of drug trials can be halted. |
 |
 |
 |
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
|
|
 |
|
|
|
|
 |
|
 |
 |
 |
|
|
|
 |
|
|
 |
|